Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease (NAFLD) [non-alcoholic steatohepatitis] patients with impaired glucose tolerance or type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 29 Feb 2012
At a glance
- Drugs Pioglitazone (Primary) ; Antihyperglycaemics
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms TOPIC
- 29 Feb 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 27 May 2008 New trial record.